The background insulin remained part of treatment
SURPASS-5 randomized 475 adults with type 2 diabetes inadequately controlled on insulin glargine, with or without metformin. It compared three tirzepatide target regimens with placebo over 40 weeks, added to titrated insulin glargine. The primary endpoint was HbA1c change; weight was a secondary endpoint. [1]
The phrase added to matters. This study did not randomly assign participants to stop insulin or use tirzepatide as their only diabetes treatment. A summary that leaves out the background regimen could encourage a fundamentally different interpretation from the question investigators actually tested.
Glucose and weight results
Average HbA1c changes were −2.11, −2.40 and −2.34 percentage points with tirzepatide 5, 10 and 15 mg, compared with −0.86 with placebo. Weight changes were −5.4, −7.5 and −8.8 kg, versus +1.6 kg. Diarrhea and nausea were the most common treatment-emergent adverse events in the tirzepatide groups. [1]
The weight result is expressed in kilograms and reflects an add-on strategy under a trial protocol. It should not be repackaged as the expected percentage loss for someone without diabetes or someone not taking insulin. The glucose and weight findings are both informative when their distinct measures remain visible.
Protocol management is part of the context
Because basal insulin was titrated during the study, the comparison involved an actively managed background treatment. A research report about that strategy cannot tell a reader how to adjust insulin independently. The individual plan requires clinical oversight that includes existing treatment and monitoring.
Discontinuation also needs its correct label. The abstract reports premature discontinuation of study treatment, which is not automatically the same as discontinuation due to side effects. A reader evaluating tolerability should resist a summary that silently substitutes one of those outcomes for the other.
The word titrated signals that background treatment was not simply frozen at enrollment. That context matters for both efficacy and safety. A clinician can explain how the trial’s monitoring compares with real care, but the article cannot reconstruct an individual insulin-management plan from the published averages.
Use the trial to clarify who manages the whole regimen
If several services are involved, ask which clinician reviews the full medication list and who is responsible for changes. A weight-management membership and a diabetes-care plan should not operate as unrelated systems. Establish how laboratory results and treatment decisions are communicated before relying on an additional provider.
Our SURPASS-6 analysis covers a different add-on comparison against mealtime insulin. It should be read separately rather than treated as an extension of this placebo comparison. The support guide helps translate the coordination issue into questions about actual care responsibilities.